search
Back to results

CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells

Primary Purpose

Chronic Renal Failure of Unknown Cause

Status
Completed
Phase
Phase 1
Locations
Nicaragua
Study Type
Interventional
Intervention
Adipose-derived stromal vascular fraction cells
Sponsored by
Samuel Vilchez
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Renal Failure of Unknown Cause focused on measuring Stromal vascular fraction, Mesenchynmal stem cells, Chronic kidney disease, Adipose stem cells

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of Mesoamerican nephropathy
  • Stages 3 and 4
  • No other renal disease
  • No essential hypertension

Exclusion Criteria:

  • Significant abnormalities in laboratory tests that contraindicate surgical procedures.
  • Acute pathology or complications of significant chronic pathologies in the 6 months prior to study entry, including, but not limited to:

Medical history of deep vein thrombosis Uncontrolled hypertension Active infection Reduced cardiac ejection fraction Hepatitis B, C or HIV Diabetes treated with insulin or glucose lowering agents Anemia (Hb <9 g/dL) History of cancer Severe depression (Beck scale) Autoimmune disease

Sites / Locations

  • Hospital Escuela Oscar Danilo Rosales Arguello

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Bilateral Treatment

Arm Description

Intra-arterial injection of SVF cells into the kidneys.

Outcomes

Primary Outcome Measures

Incidence of treatment related adverse events
Documentation of adverse events
Preliminary evidence of efficacy
Improvement in clinical parameter of GFR as compared with historical age and stage-matched controls.

Secondary Outcome Measures

Renal blood flow.
Distribution of intra-renal blood flow.
Kidney volume.
Changes in kidney size (cm3).
Renal arterial resistive index.
Decreases in hilar artery resistance index (less o equal to 0.7).

Full Information

First Posted
November 6, 2021
Last Updated
November 29, 2021
Sponsor
Samuel Vilchez
Collaborators
Ministerio de Salud de Nicaragua, GID BIO, National Autonomous University of Nicaragua
search

1. Study Identification

Unique Protocol Identification Number
NCT05154591
Brief Title
CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells
Official Title
Chronic Kidney Disease of Unknown Cause (CKDu) Treated With Directed Local Intra-arterial Infusion of Autologous Stromal Vascular Fraction (SVF) Cells.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Completed
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
February 28, 2021 (Actual)
Study Completion Date
February 28, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Samuel Vilchez
Collaborators
Ministerio de Salud de Nicaragua, GID BIO, National Autonomous University of Nicaragua

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an interventional study to treat 18 patients with chronic kidney disease of unknown cause (CKDu), formerly known as Mesoamerican nephropathy (MeN), with autologous adipose tissue-derived stromal vascular fraction (SVF) cells transplanted by intra-arterial injection both kidneys. This study assesses: (1) safety and tolerability, (2) preliminary evidence of efficacy, (3) exploratory evidence of clinical effects.
Detailed Description
Patients under go 24 hours of preoperative hydration combined with N-actyl cysteine 300 mg IV for prevention of nephrotoxicity. Under general anesthesia 200-300 cc of lipoaspirate is collected into a sterile processing cannister (GID SFV-1, Louisville, CO, USA). The tissue is washed and dissociated with collagenase (Worthington CLS-1, Lakewood, NJ, USA) at a concentration of 200 CDU/ml of total volume for 50 minutes at 39°C. This is followed by inactivation using 40 cc of human serum albumin. SVF cells are separated via centrifugation for 10 minutes at 800 g. The cell pellet is extracted and resuspended in Harmann solution with an aliquot (10 µl) removed for counting and viability assessment of resulting total nucleated cells (YNC) through and image cytometer (ADAM MC, Portsmouth NH, USA). Femoral artery catheterization is performed permitting advancement of a 100 cc balloon-tip catheter into the renal artery under fluoroscopic control, with position confirmation using 1 cc of OrtoRay® 320 contrast diluted 1:4 with Hartmann solution. SVF cells are then admixed with 200 cc Hartmann solution warmed to 37°C and in fused using a DRE infusion pump (DRE Medical, Louisville, KY, USA) over a 15 minute period with constant agitation. On the 1st pos-operative day creatinine and glomerular filtration rate are checked and the patient is discharged. Follow-up studies include clinical assessment, chemistries, and renal ultrasound to assess intra-parenchymal renal volume, renal blood flow distribution, and hilar artery vascular resistance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Renal Failure of Unknown Cause
Keywords
Stromal vascular fraction, Mesenchynmal stem cells, Chronic kidney disease, Adipose stem cells

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Open label for surgeons and radiologists Closed label for pathologists and nephrologists
Allocation
N/A
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bilateral Treatment
Arm Type
Experimental
Arm Description
Intra-arterial injection of SVF cells into the kidneys.
Intervention Type
Genetic
Intervention Name(s)
Adipose-derived stromal vascular fraction cells
Intervention Description
Kidney structural and functional changes in 18 patients after 36 months of treatment with SVF cells.
Primary Outcome Measure Information:
Title
Incidence of treatment related adverse events
Description
Documentation of adverse events
Time Frame
36-months follow-up post intervention.
Title
Preliminary evidence of efficacy
Description
Improvement in clinical parameter of GFR as compared with historical age and stage-matched controls.
Time Frame
Assessment of changes between day 7 and month 36 post intervention.
Secondary Outcome Measure Information:
Title
Renal blood flow.
Description
Distribution of intra-renal blood flow.
Time Frame
Up to month 12 post intervention.
Title
Kidney volume.
Description
Changes in kidney size (cm3).
Time Frame
Up to month 12 post intervention.
Title
Renal arterial resistive index.
Description
Decreases in hilar artery resistance index (less o equal to 0.7).
Time Frame
Up to month 12 post intervention.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of Mesoamerican nephropathy Stages 3 and 4 No other renal disease No essential hypertension Exclusion Criteria: Significant abnormalities in laboratory tests that contraindicate surgical procedures. Acute pathology or complications of significant chronic pathologies in the 6 months prior to study entry, including, but not limited to: Medical history of deep vein thrombosis Uncontrolled hypertension Active infection Reduced cardiac ejection fraction Hepatitis B, C or HIV Diabetes treated with insulin or glucose lowering agents Anemia (Hb <9 g/dL) History of cancer Severe depression (Beck scale) Autoimmune disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Carstens, MD
Organizational Affiliation
Wake Forrest Institute for Regenerative Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Diego Correa, MD, PhD
Organizational Affiliation
University of Miami
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sreedhar Mandayam, MD
Organizational Affiliation
University of Texas
Official's Role
Study Director
Facility Information:
Facility Name
Hospital Escuela Oscar Danilo Rosales Arguello
City
Leon
Country
Nicaragua

12. IPD Sharing Statement

Citations:
PubMed Identifier
28177263
Citation
Brown JC, Shang H, Li Y, Yang N, Patel N, Katz AJ. Isolation of Adipose-Derived Stromal Vascular Fraction Cells Using a Novel Point-of-Care Device: Cell Characterization and Review of the Literature. Tissue Eng Part C Methods. 2017 Mar;23(3):125-135. doi: 10.1089/ten.TEC.2016.0377.
Results Reference
result
PubMed Identifier
21726829
Citation
Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011 Jul 8;9(1):11-5. doi: 10.1016/j.stem.2011.06.008.
Results Reference
result
PubMed Identifier
33826245
Citation
Carstens MH, Quintana FJ, Calderwood ST, Sevilla JP, Rios AB, Rivera CM, Calero DW, Zelaya ML, Garcia N, Bertram KA, Rigdon J, Dos-Anjos S, Correa D. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med. 2021 Aug;10(8):1138-1147. doi: 10.1002/sctm.20-0497. Epub 2021 Apr 7.
Results Reference
result
PubMed Identifier
31054625
Citation
Correa-Rotter R, Garcia-Trabanino R. Mesoamerican Nephropathy. Semin Nephrol. 2019 May;39(3):263-271. doi: 10.1016/j.semnephrol.2019.02.004.
Results Reference
result
PubMed Identifier
26546112
Citation
Guo J, Nguyen A, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 2: Mechanisms of regenerative action. J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):180-8. doi: 10.1016/j.bjps.2015.10.014. Epub 2015 Oct 24.
Results Reference
result
PubMed Identifier
31067373
Citation
Johnson RJ, Wesseling C, Newman LS. Chronic Kidney Disease of Unknown Cause in Agricultural Communities. N Engl J Med. 2019 May 9;380(19):1843-1852. doi: 10.1056/NEJMra1813869. No abstract available.
Results Reference
result
PubMed Identifier
26565755
Citation
Nguyen A, Guo J, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD. Stromal vascular fraction: A regenerative reality? Part 1: Current concepts and review of the literature. J Plast Reconstr Aesthet Surg. 2016 Feb;69(2):170-9. doi: 10.1016/j.bjps.2015.10.015. Epub 2015 Oct 31.
Results Reference
result
PubMed Identifier
28126239
Citation
Wijkstrom J, Gonzalez-Quiroz M, Hernandez M, Trujillo Z, Hultenby K, Ring A, Soderberg M, Aragon A, Elinder CG, Wernerson A. Renal Morphology, Clinical Findings, and Progression Rate in Mesoamerican Nephropathy. Am J Kidney Dis. 2017 May;69(5):626-636. doi: 10.1053/j.ajkd.2016.10.036. Epub 2017 Jan 23.
Results Reference
result

Learn more about this trial

CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells

We'll reach out to this number within 24 hrs